Scholarlink

Background <p>Lung abscess is typically managed by performing abscess drainage. While pulmonary resection effectively controls infection, its role in eliminating necrotic tissue remains debatable due to risks such as bleeding, desaturation, systemic inflammation, persistent air leakage, and bronchopleural fistula. In this study, we evaluated the outcomes of pulmonary resection for lung abscess refractory to medical therapy.</p> Methods <p>We retrospectively analyzed 70 patients who underwent salvage thoracoscopic surgery for lung abscess, along with 60 days’ follow-up, at a tertiary referral hospital between January 2016 and August 2022. Thirty-two patients underwent lobectomy, while 38 did not. The patients’ demographics, comorbidities, disease progression, 30-day and 60-day mortality, and operative morbidity were compared between the lobectomy and non-lobectomy groups.</p> Results <p>Necrotizing pneumonia was the leading cause of lung abscess (<i>n</i> = 53, 75.7%), with empyema being the most common sign of disease progression (<i>n</i> = 36, 51.4%). The lobectomy group had a lower mortality rate compared with the non-lobectomy group (15.6% vs. 36.8%, <i>p</i> = 0.047). Multivariate analysis identified a higher Charlson Comorbidity Index (CCI) as a risk factor for 30-day mortality (HR = 1.286, 95% CI = 1.059–1.561; <i>p</i> = 0.011), while lobectomy mitigated the 30-day mortality risk (HR = 0.255, 95% CI = 0.068–0.959; <i>p</i> = 0.043). Similarly, a higher CCI augmented the 60-day mortality risk (HR = 1.317, 95% CI = 1.105–1.571; <i>p</i> = 0.002), whereas lobectomy lowered it (HR = 0.319, 95% CI = 0.110–0.921; <i>p</i> = 0.035).</p> Conclusion <p>Lobectomy significantly improves the 30- and 60-day mortality outcomes compared to non-lobectomy surgery, making it a viable option for pharmacotherapy-refractory lung abscess.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating the effectiveness of thoracoscopic intervention for pulmonary abscess: is lobectomy the optimal solution after medical therapy fails?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月17日

查看全文
  • Po-Keng Su,
  • Shun-Mao Yang,
  • Cheng-Hung How,
  • Chao-Yu Liu,
  • Ka-I Leong,
  • Jei-Kuo Lin,
  • San-Fang Chou

摘要

Background

Lung abscess is typically managed by performing abscess drainage. While pulmonary resection effectively controls infection, its role in eliminating necrotic tissue remains debatable due to risks such as bleeding, desaturation, systemic inflammation, persistent air leakage, and bronchopleural fistula. In this study, we evaluated the outcomes of pulmonary resection for lung abscess refractory to medical therapy.

Methods

We retrospectively analyzed 70 patients who underwent salvage thoracoscopic surgery for lung abscess, along with 60 days’ follow-up, at a tertiary referral hospital between January 2016 and August 2022. Thirty-two patients underwent lobectomy, while 38 did not. The patients’ demographics, comorbidities, disease progression, 30-day and 60-day mortality, and operative morbidity were compared between the lobectomy and non-lobectomy groups.

Results

Necrotizing pneumonia was the leading cause of lung abscess (n = 53, 75.7%), with empyema being the most common sign of disease progression (n = 36, 51.4%). The lobectomy group had a lower mortality rate compared with the non-lobectomy group (15.6% vs. 36.8%, p = 0.047). Multivariate analysis identified a higher Charlson Comorbidity Index (CCI) as a risk factor for 30-day mortality (HR = 1.286, 95% CI = 1.059–1.561; p = 0.011), while lobectomy mitigated the 30-day mortality risk (HR = 0.255, 95% CI = 0.068–0.959; p = 0.043). Similarly, a higher CCI augmented the 60-day mortality risk (HR = 1.317, 95% CI = 1.105–1.571; p = 0.002), whereas lobectomy lowered it (HR = 0.319, 95% CI = 0.110–0.921; p = 0.035).

Conclusion

Lobectomy significantly improves the 30- and 60-day mortality outcomes compared to non-lobectomy surgery, making it a viable option for pharmacotherapy-refractory lung abscess.